Cargando…

Considering the Experimental Use of Temozolomide in Glioblastoma Research

Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient’s survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herbener, Verena J., Burster, Timo, Goreth, Alicia, Pruss, Maximilian, von Bandemer, Hélène, Baisch, Tim, Fitzel, Rahel, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew, Strobel, Hannah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344626/ https://www.ncbi.nlm.nih.gov/pubmed/32512726 http://dx.doi.org/10.3390/biomedicines8060151

Ejemplares similares

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Comment in Response to “Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina”
por: Westhoff, Mike-Andrew, et al.
Publicado: (2020)

The effects of PI3K-mediated signalling on glioblastoma cell behaviour
por: Langhans, Julia, et al.
Publicado: (2017)

Targeting super-enhancers reprograms glioblastoma central carbon metabolism
por: Nguyen, Trang T.T., et al.
Publicado: (2021)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

The limitations of targeting MEK signalling in Glioblastoma therapy
por: Selvasaravanan, Karthika D., et al.
Publicado: (2020)

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
por: Pruss, Maximilian, et al.
Publicado: (2020)

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

Targeting cellular respiration as a therapeutic strategy in glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2023)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

What Animal Cancers teach us about Human Biology
por: Kattner, Patricia, et al.
Publicado: (2021)

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems
por: Nguyen, Trang T. T., et al.
Publicado: (2020)

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
por: Karpel-Massler, Georg, et al.
Publicado: (2014)

Killing Me Softly—Future Challenges in Apoptosis Research
por: Westhoff, Mike-Andrew, et al.
Publicado: (2014)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells
por: Hasslacher, Sebastian, et al.
Publicado: (2018)

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma
por: Thi Thu Nguyen, Trang, et al.
Publicado: (2020)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy
por: Ströbele, Stephanie, et al.
Publicado: (2015)

Cell death-based treatment of childhood cancer
por: Westhoff, Mike-Andrew, et al.
Publicado: (2018)

ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression
por: Dwucet, Annika, et al.
Publicado: (2021)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma
por: Xu, Pengfei, et al.
Publicado: (2022)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014)

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
por: Halatsch, Marc-Eric, et al.
Publicado: (2021)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
por: Nguyen, Trang T.T., et al.
Publicado: (2022)

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells
por: Burster, Timo, et al.
Publicado: (2021)

A triple drug combination as a novel anti-glioma therapy?
por: Zhang, Yiru, et al.
Publicado: (2018)

IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death
por: Karpel-Massler, Georg, et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach
por: Mettang, Melanie, et al.
Publicado: (2018)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

ETMM-05. LACTIC ACID FACILITATES GLIOBLASTOMA GROWTH THROUGH MODULATION OF THE EPIGENOME
por: Torrini, Consuelo, et al.
Publicado: (2021)

Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tulpqaanj5imj9uintac82uilk